Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
The following biotech stocks struck 52-week highs Jan. 9:
- China SXT Pharmaceuticals Inc (NASDAQ: SXTC)
- Innoviva Inc (NASDAQ: INVA)
- Organogenesis Holdings Inc (NASDAQ: ORGO)
Down In The Dumps
The following biotech stocks hit 52-week lows Jan. 9:
- Amneal Pharmaceuticals Inc (NYSE: AMRX)
Stocks In Focus Cancer Genetics Prices Common Stock Offering
The offering is expected to close on or around Jan. 14. The company said it intends to use the net proceeds to pay lender fees and other costs incurred in connection with a potential forbearance agreement to pay costs associated with its terminated transaction with NovellusDx Ltd.
The penny stock slumped 15.42 percent to 29.6 cents in after-hours trading Wednesday.
DiaMedica To Delist From Canadian Exchange
DiaMedica Therapeutics Inc (NASDAQ: DMAC) said it has decided to voluntarily delist its voting shares from the TSX Venture Exchange effective Jan. 18.
The company attributed the decision to the high financial and administrative costs associated with maintaining a dual listing.
Medigus CEO Resigns
Medical device companyMedigus ADR (NASDAQ: MDGS) said its CEO Chris Rowland will relinquish the role effective Feb. 28, although he will continue in a consulting capacity.
The company said an executive team appointed by the board will oversee Rowland's responsibilities until a replacement is named.
The stock was slipping 4.84 percent to $2.75 in premarket trading Thursday.
Heat Biologics To Present Midstage Lung Cancer Data
Heat Biologics Inc (NASDAQ: HTBX) gave an update on its business plans for 2019 and said it's expanding a Phase 2 trial of HS-110 in combination with a different anti-PD-1 checkpoint inhibitor to treat patients earlier in the course of their metastatic disease. It will make a podium presentation of interim Phase 2 lung cancer data at ASCO SITC Clinical Immuno-Oncology Symposium Feb. 28.
Heat Biologics said it remains on track to complete enrollment for a Phase 2 lung cancer trial in Q2, while it also said it has a strong balance sheet to kick off the year with.
The stock was rising 1.63 percent to $1.25 in pre-market trading Thursday.
On The Radar Earnings
- Advaxis, Inc. (NASDAQ: ADXS)
Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates
See more from Benzinga
- The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study
- The Daily Biotech Pulse: Amgen Slashes Cholesterol Drug Device Prices By 60%, Takeda Completes Shire Purchase
- 5 Top-Selling Drugs With Growth Potential In 2019
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.